EGFR and non-small cell lung carcinoma: EGFR has been clinically proven as a valuable therapeutic target for non-small cell lung cancer (NSCLC) with gefitinib and erlotinib being the most approved first-generation EGFR tyrosine kinase inhibitors [7,8].